BioScale, a company that develops, manufactures, and promotes protein analytics technology, has received $25 million in a recent financing round. The money will be used to expand manufacturing operations and commercial sales of the ViBE protein analytics systems.
“We are excited about the therapeutic and diagnostic potential of protein biomarkers and feel BioScale’s next-generation proteomics platform is well-positioned to become a leader in the protein-measurement space,” says Isaac Cheng, M.D., of Morningside Venture, the new investor that led the funding round.
Integrating simple sample preparation and microparticle techniques with novel detection and quantitation technology, BioScale’s ViBE systems reportedly deliver high performance in a wide range of applications. The ViBE systems allow customers to rapidly create and configure their own assays using the firm’s AMMP™ (acoustic membrane microparticle) technology. AMMP is a label-free, nonoptical, homogeneous assay that is well-suited for operation in complex matrices, according to BioScale.
“The financing will provide the resources to bring BioScale's ViBE product line into the market and establish BioScale as a leader in protein analytics technology,” remarks Mark Lundstrom, founder and CEO of BioScale.